מתוך medicontext.co.il
WESTPORT, CT (Reuters Health) – According to the results of animal experiments, inhibition of RXR or PPAR-gamma appears to ameliorate diet-induced obesity and type 2 diabetes.
"PPAR-gamma is a ligand-activated transcription factor and a member of the nuclear hormone receptor superfamily that functions as a heterodimer with a retinoid X receptor (RXR)," Japanese researchers explain in The Journal of Clinical Investigation for October.
Dr. Takashi Kadowaki, from the University of Tokyo in Bunkyo-ku, and colleagues treated wild-type mice with an RXR antagonist they identified, HX531, or with a PPAR-gamma antagonist, bisphenol A diglycidyl ether (BADGE). The mice were fed a high-fat diet.
By reducing triglycerides in white adipose tissue, skeletal muscle and the liver, both antagonists prevented obesity, insulin resistance and diabetes, the researchers report.
Paradoxically, Dr. Kadowaki's team found that in PPAR-gamma-deficient mice, treatment with a PPAR-gamma or RXR inhibitor decreased leptin levels and depleted white adipose tissue. This resulted in increased triglyceride levels in the liver and skeletal muscles, leading to insulin resistance.
The investigators speculate that in individuals who have wild-type PPAR-gamma (the Pro 12 allele) and are genetically susceptible to obesity and diabetes, treatment with PPAR-gamma/RXR inhibition may be protective. They caution that in individuals with variant PPAR-gamma (the Ala 12 allele), such treatment could worsen the risk of insulin resistance.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!